Drug interactions among older adults followed up in a comprehensive medication management service at Primary Care

Tayane Oliveira dos Santos¹, Mariana Martins Gonzaga do Nascimento¹, Yone Almeida Nascimento¹, Grazielli Cristina Batista de Oliveira¹, Ursula Carolina de Morais Martins¹, Danielle Fernandes da Silva¹, Djenane Ramalho de Oliveira¹

¹ Centro de Estudos em Atenção Farmacêutica, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.

DOI: 10.31744/einstein_journal/2019AO4725

ABSTRACT

Objective: To estimate the prevalence of drug interactions and associated factors among older adults followed up in a Comprehensive Medication Management Service at Primary Care. Methods: Firstly, the Beers criteria 2015 was used to define drug interactions; later, drug interactions proposed by Dumbreck for patients with diabetes, depression, and heart failure were evaluated. The associated factors were assessed by univariate (Pearson's χ²) and multivariate analyses (logistic regression). The significance level of 5% was set for all analyses. Results: The mean age of the studied population was 70.2±7.8 years; 52.2% were between 60 and 69 years, and 61.3% were female. Among the older adults, 94.5% used two or more drugs (condition for the occurrence of drug-drug interaction). The prevalence of drug interaction according to the Beers criteria was 4.9%. After multivariate analysis, diseases of the central nervous system, arrhythmia, number of medications, and female sex were positively associated with drug interaction. The prevalence of drug interaction according to Dumbreck was 27.2%. After multivariate analysis, the number of medications, the presence of heart failure, and Charlson comorbidity index greater than 1 were conditions positively associated with drug interactions. Conclusion: The holistic and individualized approach used in comprehensive medication management services for older patients is important, considering the prevalence of drug interactions and the need to minimize adverse events.

Keywords: Drug interactions; Aged; Medication therapy management; Potentially inappropriate medication list; Pharmacists

RESUMO

Objetivo: Estimar a prevalência de interações medicamentosas entre idosos acompanhados em um Serviço de Gerenciamento da Terapia Medicamentosa na Atenção Primária e fatores associados. Métodos: Para definir as interações medicamentosas, foi utilizado o critério de Beers de 2015 e, em um segundo momento, as interações medicamentosas propostas por Dumbreck para pacientes com diabetes, depressão e insuficiência cardíaca. A análise dos fatores associados foi realizada por análise univariada (χ² de Pearson) e multivariada (regressão logística). Foi adotado o nível de significância de 5% para todas as análises. Resultados: A média da idade...
Da população foi de 70,2±7,8 anos, 52,2% eram do sexo feminino, e 61,3% eram do sexo feminino. Dentre os idosos, 94,5% usavam dois medicamentos ou mais (condição para que ocorressem interações medicamentosas). A prevalência de interações medicamentosas dos critérios de Beers foi de 4,9%. Após análise multivariada, doença do sistema nervoso central, arritmia, número de medicamentos e sexo feminino foram positivamente associados com presença de interações medicamentosas. A prevalência das interações medicamentosas propostas por Dumbreck foi de 27,2%. Após análise multivariada, número de medicamentos, insuficiência cardíaca e índice de comorbidade de Charlson superior a 1 foram positivamente associados com presença de interações medicamentosas. **Conclusão:** A abordagem holística e individualizada no gerenciamento da terapia medicamentosa de pacientes idosos é importante, tendo em vista a prevalência das interações medicamentosas e a necessidade de minimizar consequentes eventos adversos.

**Descritores:** Interações medicamentosas; Idoso; Conduta do tratamento medicamentoso; Lista de medicamentos potencialmente inapropriados; Farmacêuticos

## INTRODUCTION

Demographic transition has been observed in several countries, which are at different stages and present processes with unique features. In Brazil, the increase in life expectancy and decrease in fertility rates – which are determinants in this transition process, occurred only as early as 1960.(1) Currently, there is a fast demographic aging at national level. Some projections estimate that, by 2030, the aged population will be approximately 41.5 million.(2)

With increased life expectancy and the growing number of older people, the profile of diseases changes, with greater prevalence of chronic and degenerative diseases that require continuous use of medications.(3,4) The use of multiple medications is common among older patients, putting these individuals at risk of using potentially inappropriate medications, as well as of drug interactions.(3,5)

Furthermore, aging brings physiological changes that influence the pharmacokinetics and pharmacodynamics of most drugs often used by older adults. These changes increase the frequency of adverse events associated with the use of drugs and the interactions among them.(6)

Potentially serious drug interactions, which are considered avoidable adverse events, may lead to severe and even lethal outcomes.(7) Pedrós et al.(8) estimated that one out of 30 admissions of older patients at hospital emergency departments was associated with drug-related adverse events, and about half of these was likely to be caused by drug interactions. In a meta-analysis, Dechanont et al.(9) identified that 1.1% of hospital admissions were related to drug interactions. On the other hand, McDonnell et al.(10) evaluated preventable adverse events in hospital admissions and found that approximately 26% of all admissions involved drug interactions, which could have been prematurely recognized by pharmacists and primary care health workers.

**OBJECTIVE**

To estimate the prevalence of drug interactions and associated factors among older individuals followed up in a Comprehensive Medication Management Service at Primary Care.

**METHODS**

This is a cross-sectional study carried out to estimate the prevalence of drug interactions, identify the most frequent interactions, and detect the associated factors.

All patients aged ≥60 years, as defined by the World Health Organization (WHO) for older people in developing countries, registered at the Comprehensive Medication Management Service (CMM) at the primary care setting, in the city of Lagoa Santa (State of Minas Gerais), between April 2015 and February 2016, who were taking at least two medications during the follow-up period, were included (n=436). Lagoa Santa is a city in the State of Minas Gerais (Brazil), located in the metropolitan region of Belo Horizonte, 35 km away from the capital city.

The following data were collected: sex, age, health problems, and medications used (prescribed and non-prescribed) classified according to the Anatomical Therapeutic Chemical Code Classification System (ATC). The Charlson comorbidity index (CCI) was also calculated for each of the patients included in the CMM service.(11) All data were collected retrospectively from the records of the CMM Service at the primary care setting, which are documented by the pharmacist responsible for taking caring of patients.

The data of the used drugs (prescribed and non-prescribed) were identified in the first or second visits, with the pharmacist checking the prescription and drug package, considering that often the complete list of medications used by the patient at the beginning of the care process was determined by the pharmacist only at the second visit. Among these drugs, potentially inappropriate drug interactions for the older adults were identified. For this purpose, the table of potentially clinically important non-anti-infective drug-drug interactions that should be avoided in older adults, according to the 2015 Beers criteria update, was used.(12)
Moreover, patients with diagnosis of heart failure, depression and type-2 diabetes mellitus (DM) were also identified. In the drug therapy of these patients, the potentially severe drug-drug interactions proposed by Dumbreck et al.\(^{[13]}\) were identified. This study identified the relevant interactions involving drugs used in the clinical guidelines of the National Institute of Health and Care Excellence (NICE) for the three diseases, in addition to the medications listed in nine other protocols of common diseases that patients present as comorbidities: atrial fibrillation, osteoarthritis, chronic obstructive pulmonary disease, hypertension, secondary prevention after myocardial infarction, dementia, rheumatoid arthritis, chronic kidney disease, and neuropathic pain.

The descriptive analysis of data was conducted by determining the absolute and relative frequencies of the qualitative variables, and the mean and standard deviation of the quantitative variables.

Two dependent variables were defined for the univariate and multivariate analyses: the identification of at least one drug interaction according to the Beers criteria;\(^{[12]}\) and the identification of at least one drug interaction according to Dumbreck et al.\(^{[13]}\)

The following independent variables were evaluated by taking both dependent variables: sex, age (60-69 years versus 70-98 years), number of health problems (0-4 health problems versus 5 or more), number of medications used (2-5 medications versus 6 or more), CCI (0 versus 1 or more), diagnosis of hypertension (yes versus no), diagnosis of DM (yes versus no), diagnosis of heart failure (yes versus no), diagnosis of depression disorder (yes versus no), diagnosis of arrhythmia (yes versus no), and central nervous system diseases (yes versus no). The quantitative variables (age, number of health problems selected, number of medications and CCI) were divided according to their median. For the variable CCI, we chose to use the original version of the score without including the age group in the calculation of severity, since age is also used as an independent variable in multivariate models.

For univariate analysis, Pearson’s \(\chi^2\) test was used, or Fisher’s exact test, when the expected value of one or more cells was five or less. Independent variables with \(p<0.20\) in the univariate analysis were included in the multivariate model calculated by stepwise logistic regression. The Hosmer-Lemeshow test was used to evaluate the quality of adjustment of the multivariate model. The univariate and multivariate analyses were based on the odds ratio (OR) and the respective 95% confidence interval (95% CI), as estimated by logistic regression. The level of significance of 5% was the criterion adopted to identify the characteristics independently associated to the dependent variable.

The information collected was entered into the Excel\(^{®}\) spreadsheets, and then transferred to and organized in a Stata\(^{®}\) 12 database software (Stata Corp. College Station, USA).

This study is part of the Clinical, Economic, Humanistic, Cultural, and Educational Aspects of Comprehensive Medication Management Services, at the Brazilian National Health System project, approved by the Internal Review Board of the Universidade Federal de Minas Gerais, under protocol CAAE: 25780314.4.0000.5149.

## RESULTS

Older patients who used two or more medications (n=408) - condition necessary for drug interaction, were included in the study. The mean age was 70.2±7.8 years (minimum: 60, maximum: 98 years), and most were in the age range 60-69 years (52.2%, n=213), and were female (61.3%, n=250). The mean number of health problems was 3.4±1.5, and, regarding drug use, the majority used five or more medications (54.9%; n=184) with a mean of 5.1±2.3 medications.

Considering the drug interactions according to the Beers criteria, 22 interactions were identified in 20 patients, with a prevalence of 4.9% in the studied population. The association of three or more drugs acting in the central nervous system was the most common interaction, found in 3.2% of the older adults (Table 1).

In the multivariate analysis of association with the presence of drug-drug interactions proposed by Beers, the existence of a central nervous system disease was the most strongly associated variable (OR=10.8; 95%CI: 3.82-30.57; \(p>0.05\)). Arrhythmia, female sex and use of six or more drugs also remained associated with the presence of the drug interactions proposed by Beers in multivariate analyses (Table 2).

Regarding the drug interactions proposed by Dumbreck et al.,\(^{[13]}\) 210 interactions were identified in 111 patients (27.2%), and 11.5% had 2 or more drug interactions. Considering the disease involved in the interaction, among the patients with DM, 150 interactions were identified (71.4%); with heart failure, 50 (23.8%); and with depression, 10 (4.8%). The three most common interactions were in patients with DM, mostly involving angiotensin II receptor antagonists (AT1 subtype) and diuretics used to treat hypertension, present in the drug therapy of 11.8% of patients evaluated; angiotensin converting enzyme (ACE)
### Table 1. Potentially clinically important non-anti-infective drug-drug interactions that should be avoided in older adults, according to Beers criteria

| Drug interaction                                      | Potential adverse event         | Interactions n (%) |
|-------------------------------------------------------|---------------------------------|--------------------|
| Use of three or more drugs that act on the CNS        | Falls and fractures             | 13 (59.1)          |
| Association with anti-cholinergic drugs               | Cognitive decline               | 4 (18.2)           |
| Alpha-1 antagonist versus loop diuretics              | Urinary incontinence in older women | 4 (18.2)          |
| Warfarin versus amiodarone                            | Bleeding                        | 1 (4.5)            |
|                                                       | Total                            | 22 (100)           |

CNS: central nervous system.

### Table 2. Univariate and multivariate analyses of the factors associated to drug-drug interactions, according to the Beers criteria

| Variables                              | Drug-drug interactions* | Univariate | Multivariate |
|----------------------------------------|-------------------------|------------|--------------|
|                                        | Yes n (%)               | No n (%)   | OR (95%CI)†  | p value p‡ | OR (95%CI)§ | p value p§ |
| Sex                                    |                         |            |              |           |              |           |
| Male                                   | 3 (15.0)                | 155 (39.9) | 1            | 1         |              | 1         |
| Female                                 | 17 (85.0)               | 233 (60.1) | 3.77 (1.08-13.08) | 0.026     | 4.45 (1.18-16.73) | 0.027     |
| Age                                    |                         |            |              |           |              |           |
| ≤60-69                                 | 12 (5.6)                | 201 (94.4) | 1            |           |              |           |
| >70                                    | 8 (4.1)                 | 187 (95.9) | 0.72 (0.28-1.79) | 0.474     |              |           |
| Number of drugs                        |                         |            |              |           |              |           |
| ≤2                                    | 6 (2.3)                 | 253 (97.7) | 1            |           |              |           |
| >2                                    | 14 (9.4)                | 135 (90.6) | 4.37 (1.64-11.64) | 0.001     | 3.41 (1.21-9.57) | 0.020     |
| Number of health problems              |                         |            |              |           |              |           |
| 0 or more                              | 13 (4.0)                | 312 (96.0) | 1            |           |              |           |
| ≥5 or more                             | 7 (8.4)                 | 76 (91.6)  | 2.21 (0.85-5.73) | 0.095     |              |           |
| Charlson comorbidity index             |                         |            |              |           |              |           |
| 0 or more                              | 10 (5.4)                | 177 (94.7) | 1            |           |              |           |
| >1 or more                             | 10 (4.5)                | 211 (95.5) | 0.84 (0.34-2.06) | 0.701     |              |           |
| Hypertension                           |                         |            |              |           |              |           |
| No                                     | 3 (7.0)                 | 40 (93.0)  | 1            |           |              |           |
| Yes                                    | 17 (4.5)                | 348 (95.5) | 0.65 (0.18-2.32) | 0.505     |              |           |
| Diabetes                               |                         |            |              |           |              |           |
| No                                     | 14 (5.7)                | 234 (94.3) | 1            |           |              |           |
| Yes                                    | 6 (3.7)                 | 154 (96.3) | 0.66 (0.24-1.73) | 0.387     |              |           |
| Heart failure                          |                         |            |              |           |              |           |
| No                                     | 19 (4.9)                | 366 (95.1) | 1            |           |              |           |
| Yes                                    | 1 (4.3)                 | 22 (95.7)  | 0.88 (0.11-6.85) | 0.899     |              |           |
| Depression                             |                         |            |              |           |              |           |
| No                                     | 15 (75.0)               | 366 (25.0) | 1            |           |              |           |
| Yes                                    | 5 (25.0)                | 22 (75.0)  | 5.54 (1.85-16.65) | 0.001     |              |           |
| Arrhythmia                             |                         |            |              |           |              |           |
| No                                     | 18 (90.0)               | 380 (10.0) | 1            |           |              |           |
| Yes                                    | 2 (10.0)                | 8 (90.0)   | 5.27 (1.04-26.67) | 0.025     | 9.46 (1.57-56.72) | 0.014     |
| Central nervous system disease         |                         |            |              |           |              |           |
| No                                     | 11 (55.0)               | 355 (45.0) | 1            |           |              |           |
| Yes                                    | 9 (45.0)                | 33 (55.0)  | 8.80 (3.40-22.77) | 0.000     | 10.6 (3.82-30.57) | 0.000     |

* At least one drug interaction found in the first or second visits; † estimated by logistic regression; ‡ estimated by Pearson’s χ² test; § estimated by stepwise logistic regression.

OR: odds ratio; 95%CI: 95% confidence interval.
inhibitors and diuretics used to treat hypertension were found in 7.6% of patients evaluated; and calcium channel blockers and statins, in 6.4% (Table 3).

In the multivariate analyses of the factors associated with drug interactions as proposed by Dumbreck et al.,(13) CCI greater than 1 was the most strongly associated variable (OR=23.52; 95%CI: 9.18-60.28; p>0.05). Heart failure and use of six or more drugs were also associated with drug interactions as proposed by Dumbreck et al.(13) in the multivariate analyses (Table 4).

### DISCUSSION

The prevalence of drug interactions identified according to the Beers criteria was low in our study (4.9%), and lower than that found by Bo et al.,(14) among older adults being discharged from hospital in an Italian study (7.8%). To our knowledge, that was the only study to use the Beers criteria with the same purpose of this study.(12,14) Despite the low prevalence, it should be noted that the type of interactions detected by the Beers criteria presents a considerable potential to cause severe harm to the geriatric population.(12)

| Drug interaction | Potential adverse event | n (%) |
|------------------|-------------------------|-------|
| **Diabetes mellitus** | | |
| Angiotensin II receptor antagonists (AT1 subtype) versus diuretics to treat hypertension | Hypotensive effect | 46 (22.9) |
| ACE inhibitors versus diuretics to treat hypertension | Hypotensive effect | 31 (14.8) |
| Calcium channel blockers versus statin | Myopathy | 26 (12.4) |
| **Beta blockers versus calcium channel blockers** | | |
| Beta blockers versus calcium channel blockers | Bradycardia | 21 (10.0) |
| **Alpha antagonists versus diuretics to treat hypertension** | | |
| Alpha antagonists versus diuretics to treat hypertension | Hypotensive effect | 4 (1.9) |
| **Beta blockers versus alpha antagonists** | | |
| Beta blockers versus alpha antagonists | Hypotensive effect | 3 (1.4) |
| **Alpha antagonists versus calcium channel blockers** | | |
| Alpha antagonists versus calcium channel blockers | Hypotensive effect | 3 (1.4) |
| **Angiotensin II receptor antagonists (AT1 subtype) versus spironolactone** | | |
| Angiotensin II receptor antagonists (AT1 subtype) versus spironolactone | Hyperkalemia | 3 (1.4) |
| **Fibrates versus statins** | | |
| Fibrates versus statins | Myopathy | 3 (1.4) |
| **ACE inhibitors versus spironolactone** | | |
| ACE inhibitors versus spironolactone | Hyperkalemia | 2 (1.0) |
| **Sulfonlurea versus NSAID** | | |
| Sulfonlurea versus NSAID | Abnormal PC*, requiring dose adjustment or cautious monitoring | 2 (1.0) |
| **Alpha antagonists versus spironolactone** | | |
| Alpha antagonists versus spironolactone | Hypotensive effect | 1 (0.5) |
| **Tadalafil versus alpha antagonists** | | |
| Tadalafil versus alpha antagonists | Hypotensive effect | 1 (0.5) |
| **Digoxin versus diuretics to treat hypertension** | | |
| Digoxin versus diuretics to treat hypertension | Hypokalemia | 1 (0.5) |
| **Sulfonlurea versus warfarin** | | |
| Sulfonlurea versus warfarin | Abnormal PC*, requiring dose adjustment or cautious monitoring | 1 (0.5) |
| **Depression** | | |
| SSRI versus acetylsalicylic acid | Bleeding | 2 (1.0) |
| Venlafaxine versus acetylsalicylic acid | Bleeding | 2 (1.0) |
| SSRI versus tricyclic drugs | Ventricular arrhythmias | 2 (1.0) |
| SSRI versus antipsychotics | Ventricular arrhythmias | 2 (1.0) |
| SSRI versus clopidogrel | Bleeding | 1 (0.5) |
| Antipsychotics versus diuretics | Ventricular arrhythmias | 1 (0.5) |
| **Heart failure** | | |
| ACE inhibitors versus to treat hypertension | Hypotensive effect | 11 (5.2) |
| Angiotensin II receptor antagonists (AT1 subtype) versus diuretics to treat hypertension | Hypotensive effect | 9 (4.3) |
| Digoxin versus diuretics to treat hypertension | Hypokalemia | 6 (2.9) |
| ACE inhibitors versus spironolactone | Hyperkalemia | 5 (2.4) |
| Angiotensin II receptor antagonists (AT1 subtype) versus spironolactone | Hyperkalemia | 5 (2.4) |
| Amlodipine versus simvastatin | Myopathy | 4 (1.9) |
| Digoxin versus spironolactone | Abnormal PC*, requiring dose adjustment or cautious monitoring | 3 (1.4) |
| Acetylsalicylic versus SSRI | Bleeding | 2 (1.0) |
| Beta blockers (HF) versus nifedipine | Bradycardia | 2 (1.0) |
| Beta blockers (HF) versus alpha antagonists | Hypotensive effect | 1 (0.5) |
| Amlodipine versus alpha antagonists | Hypotensive effect | 1 (0.5) |
| Beta blockers (HF) versus amiodarone | Bradycardia | 1 (0.5) |
| **Total** | | 210 (100) |

ACE: angiotensin converting enzyme; NSAID: non-steroidal anti-inflammatory drugs; PC: clinically significant in plasma concentration; SSRI: selective serotonin reuptake inhibitors; HF: heart failure.
The most frequent interaction according to the Beers criteria in our study (3.2%) was with three or more drugs that act on the central nervous system, which is associated with an increased risk of falls and fractures, especially in the older people with a history of falls.\(^{(12,15)}\) Several studies with older patients demonstrated the association of drugs that act on the central nervous system with falls and fractures.\(^{(16,17)}\) We, therefore, emphasize the need to comprehensively manage drug therapy in older patients, with a focus on reducing the use of drugs that act on the central nervous system, as well as choosing medications associated with lower risk and lower effective doses when indicated.\(^{(15,16)}\) The association of anticholinergic drugs and the interaction between alpha-1 antagonists and loop diuretics were also identified in four patients (1.0%
Drug interactions among older adults followed up in a comprehensive medication management service at Primary Care

prevalence for each interaction). The anticholinergic cognitive burden of drugs is assessed by the affinity for muscarinic receptors and their clinically relevant negative cognitive effects, being related to the number of anticholinergic drugs in use.\(^{(18)}\) Hence, the use of several drugs with this property, however of low intensity, significantly increases the risk of cognitive impairment and dementia.\(^{(15,18)}\) On the other hand, the drug interaction between alpha-1 antagonists and loop diuretics puts the older adults at higher risk of developing urinary incontinence, and consequently, more serious adverse events, such as falls and fractures.\(^{(19)}\)

In the multivariate analysis, Bo et al.\(^{(14)}\) evaluated the drug interactions and the use of potentially inappropriate medications and, as in this study, identified an association between the number of drugs in use and drug interactions. Female patients were also the majority in the Italian study, however no association between drug interactions and sex was identified. On the other hand, in the present study, among the patients with drug interactions as proposed by Beers, female sex, central nervous system diseases and arrhythmias were factors positively and strongly associated with the drug interactions. This shows the importance of careful evaluation of such interactions among older patients with this profile.\(^{(12)}\) These groups of associated diseases, those involving the central nervous system and arrhythmias, have prognoses and treatment regimens that are complex and could make the management by primary care providers difficult. These conditions encompass important criteria for referral; however, further studies applying the Beers criteria for drug interactions are necessary to evaluate its applicability.\(^{(12)}\)

In our search, we did not identify studies evaluating interactions between two drugs in the presence of specific diseases, or the list of drug interactions proposed by Dumbreck et al.\(^{(13)}\) We observed a high prevalence of disease-drug-drug interactions (27.2%), which was higher than the prevalence we found using the Beers criteria (4.9%) and of studies that evaluated disease-drug or drug-drug interactions with other lists of interactions, including in Brazil, ranging from 7.8 to 18.9%.\(^{(12,14,17,20,23)}\)

Among diabetic patients, the two most frequent interactions were between angiotensin II receptor antagonists and ACE inhibitors with diuretics to treat hypertension, which are interactions of similar mechanisms, due to the pharmacodynamics of the classes involved. In patients with heart failure, the most frequent interaction was between ACE inhibitors and diuretics to treat hypertension. For patients with diabetes and heart failure, the risk of hypotension due to the association of ACE inhibitors or angiotensin II receptor antagonists with diuretics to treat hypertension becomes even more clinically relevant.\(^{(13)}\) This hypotension is a consequence of the sodium depletion produced by the ACE inhibitor that is potentiated by the additive action of the diuretic. Such reaction is more significant in the beginning of a combination treatment.\(^{(22,25)}\) Although this association increases natriuresis, ACE inhibitors can also reduce glomerular filtration, diuresis, and the natriuretic response to diuretics.\(^{(24)}\)

Other drug interactions most commonly identified among diabetic patients were between beta-blockers and calcium channel blockers, and between statins and calcium channel blockers, with the respective adverse events, increased risk of bradycardia, and myopathy/rhabdomyolysis. The association of beta-blockers and calcium channel blockers has great therapeutic value, decreasing mortality in patients with ischemic syndromes.\(^{(23,25)}\) Nevertheless, there is a consequent blockade of reflex beta-adrenergic responses, which may increase therapeutic efficacy and also cause adverse events, such as bradycardia and hypotension. Older patients or individuals with other cardiovascular comorbidities are more susceptible and require dose adjustment in order to achieve control of symptoms.\(^{(24,25)}\)

We also underscore that, among the older adults evaluated, interactions involving beta-blockers and non-dihydropyridine calcium channel blockers were detected, further increasing the risk of adverse events related to bradycardia.

Among the statin group, simvastatin has greater potential for interaction with other classes, especially with calcium channel blockers, with an increased risk of myopathy and rhabdomyolysis, which are severe events, despite their low prevalence.\(^{(23,24)}\) Nguyen et al.\(^{(26)}\) evaluated the use of statins and risk factors for myopathy and rhabdomyolysis, and identified that diabetes and cardiovascular disease are among the co-morbidities with the higher associated risk. For patients with these comorbidities and indication of concurrent administration, adjustment of the statin dose is also recommended: for the combination with diltiazem and verapamil, the dose of simvastatin should not exceed 10mg per day; with amlodipine, not exceed 20mg per day.\(^{(24)}\)

In the multivariate analyses of disease-drug-drug interactions proposed by Dumbreck et al.,\(^{(13)}\) CCI was the variable most strongly associated with the detection of interactions (OR = 23.52; 95%CI: 9.18 – 60.28; p>0.05). In the study by Teramura-Grönblad et al.,\(^{(27)}\) who evaluated only drug-drug interactions, CCI
had no significant association with drug interactions. This result may be related to the presence of diabetes with complications and heart failure among the 17 comorbidities involved in the calculation of CCI.

Other variables associated with the multivariate analysis of disease-drug-drug interactions proposed by Dumbreck et al.\(^{13}\) were the use of six or more drugs, and the presence of heart failure. Our results coincide with those of other studies of non-hospitalized patients, which identified that the use of multiple drugs is associated with drug interactions\(^{21,27,28}\) and also to the occurrence of adverse events resulting from these interactions.\(^{29}\) Cardiovascular diseases have been associated with drug interactions,\(^{27,28}\) which often require the combination of drugs in the treatment, as well as in patients with heart failure. Busa et al.\(^{30}\) also identified a correlation between an increased number of drugs prescribed and an increase in drug interactions. In addition, drugs that act on the cardiovascular system was the main group involved in the drug interactions identified.

Regardless of the low prevalence of interactions identified for both references used, it is important to note that pharmacokinetic and pharmacodynamic changes associated with aging and illnesses related to the health problems, adopted as parameters for Dumbreck et al.\(^{13}\) are common. Reduced metabolism and excretion of various drugs and metabolites, thinning of the blood-brain barrier and greater responsiveness to central nervous system depressants are some examples. These changes potentiate the occurrence of adverse events resulting from drug interactions, intensifying the need for meticulous evaluation of drug therapy among geriatric patients.\(^{6,13}\) On the other hand, it is important to note that often the prescription of two or more drugs that interact with each other is necessary to meet the specific demands of the patient, and the prescriber should decide whether to include them in the patient's therapy. The multiprofessional team should monitor.

According to our search, this study is among the first to point out the prevalence of potentially clinically important non-anti-infective drug-drug interactions that should be avoided in the older adults. It is also the first to evaluate the prevalence of disease-drug-drug interactions as proposed by Dumbreck et al.\(^ {13}\)

This study has the limitation of retrospectively applying the interactions of the 2015 version of the Beers criteria,\(^ {12,12}\) as well as the interactions proposed by Dumbreck et al.\(^ {13}\) Another limitation was the non-assessment of frailty of older adults included in it, since this factor has considerable relevance regarding the potential clinical consequences of drug interactions.

### CONCLUSION

Among the older patients evaluated, drug-drug interactions were found according to the Beers criteria, with significant association with the use of multiple medications, female sex and central nervous system disease. Regarding the disease-drug-drug interactions as proposed by Dumbreck et al. these interactions were significantly associated with the use of multiple medications, heart failure, and the Charlson comorbidity index greater than 1.

It is worth emphasizing the importance of a holistic and individualized approach to the management of drug therapy in older patients, as provided in Comprehensive Medication Management services, which assess the totality of the individual as well as the drugs in use, drug interactions and multiple health problems, with a focus on prolonging longevity, minimizing unnecessary drug use, and decreasing adverse events and costs.

### REFERENCES

1. Closs VE, Schwanke CA. A evolução do índice de envelhecimento no Brasil, nas suas regiões e unidades federativas no período de 1970 a 2010. Rev Bras Geriatr e Gerontol. 2012;15(3):443-58.
2. Instituto Brasileiro de Geografia e Estatística (IBGE). Mudança Demográfica no Brasil no início do Século XXI. Subsídios para as Projeções da População. Rio de Janeiro: IBGE; 2015.
3. Nascimento MG, Lima-Costa MF, Loyola-Filho AI. Potentially inappropriate medication use among brazilian elderly: a population-based pharmacoepidemiological study. Lat Am J Pharm. 2016;35(4):659-66.
4. Araújo CC, Magalhães SS, Chaimowicz F. Uso de medicamentos inadequados e polifarmácia entre idosos do Programa Saúde da Família. Lat Am J Pharm. 2010;29(2):178-84.
5. Carvalho MF, Romancio-Lieber NS, Bergsten-Mendes G, Secoli SR, Ribeiro E, Lebrão ML, et al. Polyprescribing among the elderly in the city of São Paulo, Brazil - SABE. Rev Bras Epidemiol. 2012;15(4):817-27.
6. Davies EA, O’Mahony MS. Adverse drug reactions in special populations: the elderly. Br J Clin Pharmacol. 2015;80(4):796-807.
7. Guthrie B, Makubate B, Hernandez-Santiago V, Dreishclute T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015;13(74):1-10.
8. Pedrós C, Formiga F, Corbella X, Arnau JM. Adverse drug reactions leading to urgent hospital admission in an elderly population: prevalence and main features. Eur J Clin Pharmacol. 2016;72(2):219-26.
9. Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/ visits associated with drug–drug interactions: a systematic review and meta-analysis. Pharmacoeconomics Drug Saf. 2014;23(5):489-97. Review.

### AUTHORS´ INFORMATION

Santos TO: http://orcid.org/0000-0002-9140-1680  
Nascimento MM: http://orcid.org/0000-0003-2183-4365  
Nascimento YA: http://orcid.org/0000-0002-5897-0160  
Oliveira GC: http://orcid.org/0000-0002-8980-9097  
Martins UC: http://orcid.org/0000-0001-8616-7351  
Silva DF: http://orcid.org/0000-0002-3198-7229  
Ramalho de Oliveira D: http://orcid.org/0000-0002-5548-8184
10. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36(9):1331-6.

11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.

12. American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227-46.

13. Dumbreck S, Flynn A, Nairn M, Wilson M, Trew S, Mercer SW, et al. Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ. 2015;350:h949.

14. Bo M, Quaranta V, Fonte G, Falcione Y, Carignano G, Cappa G. Prevalence, predictors and clinical impact of potentially inappropriate prescriptions in hospital-discharged older patients: a prospective study. Geriatr Gerontol Int. 2018;18(4):561-8.

15. Hanlon JT, Semla TP, Schmader KE. Alternative medications for medications in the use of high-risk medications in the elderly and potentially harmful drug-disease interactions in the elderly quality measures. J Am Geriatr Soc. 2015;63(12):e8-18.

16. Aspinall SL, Zhao X, Semla TP, Cunningham FE, Paquin AM, Pugh MJ, et al. Epidemiology of drug–disease interactions in older veteran nursing home residents. J Am Geriatr Soc. 2015;63(1):77-84.

17. Naples JG, Marcum ZA, Perera S, Newman AB, Greenspan SL, Gray SL, et al. Impact of drug-drug and drug-disease interactions on gait speed in community-dwelling older adults. Drugs Aging. 2016;33(6):411-8.

18. Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361:k3151.

19. Peron EP, Zheng Y, Perera S, Newman AB, Resnick NM, Shorr RI, Bauer DC, Simonsonick EM, Gray SL, Hanlon JT, Ruby CM; Health, Aging, and Body Composition (Health ABC) Study. Antihypertensive drug class use and differential risk of urinary incontinence in community-dwelling older women. J Gerontol A Biol Sci Med Sci. 2012;67(12):1373-8.

20. Jhaveri BN, Patel TK, Barvaliya MJ, Tripathi C. Utilization of potentially inappropriate medications in elderly patients in a tertiary care teaching hospital in India. Perspect Clin Res. 2014;5(4):184-9.

21. Novaes PH, da Cruz DT, Lucchetti AL, Leite CG, Lucchetti G. The "iatrogenic triad": polypharmacy, drug–drug interactions, and potentially inappropriate medications in older adults. Int J Clin Pharm. 2017;39(4):818-25.

22. Izzo JL Jr, Weir MR. Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich). 2011;13(9):667-75. Review.

23. Secoli SR, Danzi NJ, Lima FF, Lorenzi Filho G, Cesar LA. Interações medicamentosas em pacientes coronariopatas. Rev Bras Cardiol. 2012;25(1):11-8.

24. Micromedex® Healthcare Series [Internet]. Greenwood Village (US): Thomson Reuters (Healthcare); 2018 [cited 2018 Out 16]. Available from: https://rdl.lib.uconn.edu/databases/919

25. Sagie A, Strasberg B, Kusnieck J, Sclarovsky S. Symptomatic bradycardia induced by the combination of oral diltiazem and beta blockers. Clin Cardiol. 1991;14(4):314-6.

26. Nguyen KA, Li L, Lu D, Yazdanparast A, Wang L, Kreutz RP, et al. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. Eur J Clin Pharmacol. 2018;74(9):1099-109. Review.

27. Teramura-Grönblad M, Raivio M, Savikko N, Muurinen S, Soini H, Suominen M, et al. Potentially severe drug-drug interactions among older people and associations in assisted living facilities in Finland: a cross-sectional study. Scand J Prim Health Care. 2016;34(3):250-7.

28. Dubova Dubova SV, Reyes-Morales H, Torres-Arreola LP, Suárez-Ortega M. Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC Health Serv Res. 2007;7:147.

29. Moura CS, Acuário F, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009;12(3):266-72.

30. Busa G, Burlina A, Damuzzo V, Chiumente M, Palazzo AC. Comorbidity, polytherapy, and drug interactions in a neurological context: an example of a multidisciplinary approach to promote the rational use of drugs. J Pharm Pract. 2018;31(1):58-65.